MétaCan
Menu
Retour à la cohorte
Enregistrement W4406483050 · doi:10.4103/aomd.aomd_74_24

Botulinum toxin beyond borders: Enhancing global access and understanding

2025· article· en· W4406483050 sur OpenAlexaboutno aff
Muhammad Arsalan Bashir, Aashar Khalid

Notice bibliographique

RevueAnnals of Movement Disorders · 2025
Typearticle
Langueen
DomaineMedicine
ThématiqueBotulinum Toxin and Related Neurological Disorders
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésBotulinum toxinToxinBusinessComputer scienceNeurosciencePsychologyBiologyMicrobiology

Résumé

récupéré en direct d'OpenAlex

Dear Sir, Initially approved by the FDA in 1989, botulinum toxin A, was developed as a surgical alternative for strabismus patients.[1,2] Since then, its use has expanded, particularly in cosmetic treatments for wrinkles and facial esthetics.[3] Derived from Clostridium botulinum, botulinum toxin is a neurotoxin that prevents acetylcholine release, causing muscle paralysis. This mechanism is key to its safe and effective use in medicine.[1] Botulinum toxin is indicated for a wide range of conditions, with many uses being off-label; FDA-approved indications include chronic migraine, cervical dystonia, blepharospasm, strabismus, primary axillary hyperhidrosis, adult bladder dysfunction, pediatric detrusor overactivity, spasticity, and cosmetic applications. Off-label uses encompass the neurogenic thoracic outlet syndrome, epicondylitis, and various types of pain (post-stroke, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic, spinal cord injury-related, myofascial, and bladder pain), often as an alternative or last-resort treatment.[4] The preference of botulinum toxin over pharmacological treatments stems from its significant therapeutic benefits in conditions such as chronic migraine, cervical dystonia, and overactive bladder, as evidenced by studies highlighting its efficacy, safety, and tolerability.[4-6] As a minimally invasive option, botulinum toxin broadens the spectrum of patient treatment choices.[7] Patients often choose botulinum toxin due to its perceived effectiveness and preference for therapeutic injections over oral medications. In particular, in conditions such as overactive bladder, botulinum toxin is favored over treatments such as sacral neuromodulation.[6,7] In addition, botulinum toxin is the preferred treatment for specific conditions such as laryngeal dystonia and voice tremors.[8] Its non-invasive application and perceived benefits make botulinum toxin a favored choice over traditional pharmacological therapies in various medical scenarios. While botulinum toxin is generally considered safe, it is important to remain vigilant about its potential risks. Research has highlighted concerns regarding health hazards associated with counterfeit botulinum toxin injections, which can result in severe botulism cases.[9] Furthermore, the benefits of botulinum toxin are temporary, requiring repeated treatments and emphasizing the need for cautious utilization.[10-12] The production of botulinum toxin is a sophisticated process that demands exacting precision and expertise. Its effectiveness hinges on the potency of the botulinum neurotoxin. A specific cell-based potency assay for botulinum neurotoxin serotype A has been developed and approved by regulatory agencies such as the FDA, Health Canada, and the European Union to ensure consistent quality.[13] Although neurologists often prefer botulinum toxin over medications for specific conditions due to its fewer side effects and widespread off-label use, its cost effectiveness remains a topic of investigation. Some studies propose that botulinum toxin may be more cost effective than alternative treatments for various medical conditions.[14] However, evaluating the cost effectiveness of botulinum toxin requires considering dosing, treatment duration, and patient demographics.[15] The availability of botulinum toxin in underdeveloped countries poses a significant challenge due to costs and limited healthcare resources. While botulinum toxin is a common treatment globally, its accessibility in less developed nations is often restricted by economic and infrastructural barriers. The cost of botulinum toxin per patient per injection compared to other botulinum toxin products, such as Dysport, differs worldwide, with Dysport often being the less expensive option.[16] The rising popularity of botulinum toxin is due to its high effectiveness, fewer side effects, and lasting benefits, making it an indispensable medication. However, as global demand increases, improving its availability beyond Western countries becomes more urgent. Concerns about immunoresistance,[17] particularly in the Asian population, requires additional research. Furthermore, environmental factors, such as the heat in equatorial regions, may compromise the efficacy of botulinum toxin. Popularized by celebrities and social media as a cosmetic treatment, botulinum toxin can inadvertently reduce patients’ willingness to pay for a treatment perceived as cosmetic rather than therapeutic.[18] This poses as a significant barrier to neurologists or medical specialists when discussing botulinum toxin as a treatment option. In addition, a general lack of knowledge about proper usage frequencies and techniques, coupled with incorrect application, may lead to adverse effects and suboptimal results. The high import costs, resulting from the lack of local manufacturing, further exacerbate the situation. To better the reach and impact of botulinum toxin in economically disadvantaged areas, a comprehensive plan is advised. This plan should involve forming subsidies with international health bodies, enhancing the expertise of local medical staff in administering botulinum toxin, and upgrading healthcare facilities for optimal botulinum toxin storage and management. Investigating the potential for in-country production under stringent quality checks could help decrease expenses, while educational programs could boost understanding of the medical advantages of botulinum toxin. By implementing these measures, botulinum toxin could become a more accessible and cost-effective healthcare option in resource-scarce regions, significantly improving the well-being and health outcomes of patients. Authors’ contributions AK: Made substantial contributions to the conception and design of the study, and the drafting and revising of the manuscript. MAB: Made substantial contributions to the design and implementation of the research, and the critical revision of the manuscript. Research project: Conception: Aashar Khalid, Muhammad A. Bashir Organization: Muhammad A. Bashir Execution: Muhammad A. Bashir Statistical analysis: Design: Aashar Khalid, Muhammad A. Bashir Execution: Muhammad A. Bashir Review and Critique: Aashar Khalid, Muhammad A. Bashir Manuscript preparation: Writing of the first draft: Review and Critique: Muhammad A. Bashir, Aashar Khalid Ethical compliance statement No ethical concerns as no human subjects or patients were involved in the study. The authors have reviewed the journal’s ethical publication guidelines and attest that this submission adheres to them. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Théorique ou conceptuel · Signal consensuel: aucune
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,517
Score d'incertitude au seuil0,882

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0000,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,001
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,054
Tête enseignante GPT0,371
Écart entre enseignants0,317 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeThéorique ou conceptuel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2025
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueAnnals of Movement DisordersMême sujetBotulinum Toxin and Related Neurological DisordersTravaux en français237 207